Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01205321 | PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers | PHASE1 | COMPLETED | 19 | — | — | Nov 1, 2010 | Dec 1, 2011 | Jan 21, 2013 | 3 | Finland, Germany +1 |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Bombesin (68Ga) labeled (BAY86-7548) | DRUG | Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT |
Inclusion Criteria: * Healthy volunteers: * males, \>/=50 and \</= 65 years of age * Cancer patients: * males \>/= 45 years of age * Patients had an MRI of the prostate and/or a positive choline or acetate PET/CT for diagnosis (Note: MRI, choline and acetate PET/CT are optional for primary ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Hologic, Inc. | HOLX | 1 | NA | Undisclosed |
| Intelligent Bio Solutions Inc. | INBS | 1 | — | Undisclosed |
| HeartFlow, Inc. | HTFL | 1 | NA | Rosuvastatin |
| GE Healthcare Technologies Inc. | GEHC | 2 | NA | Undisclosed |
| Unity Health Toronto | UBX | 1 | — | Undisclosed |